Actively Recruiting
PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer
Led by Atlas University · Updated on 2026-01-27
160
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy controls (n=40). The primary objective is to identify serum biomarkers that differentiate metastatic from non-metastatic disease. Secondary analyses will evaluate correlations between biomarker levels and organ-specific metastatic involvement, including bone, lung, liver, and brain metastases. Findings from this study may support the development of a noninvasive serum-based tool for predicting metastatic patterns in breast cancer.
CONDITIONS
Official Title
PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female individuals aged 6518 years
- Ability to provide written informed consent
- Histopathologically confirmed breast cancer with distant organ metastasis for metastatic group
- Histopathologically confirmed breast cancer with no evidence of distant metastasis for non-metastatic group
- Women aged 6518 years with no known breast disease and no personal history of malignancy for healthy controls
You will not qualify if you...
- History of any other primary malignancy
- Known breast disease or breast cancer diagnosis in healthy control group
- Receiving immunosuppressive therapy that may affect immune or biomarker profiles
- Active infection or inflammatory condition that may affect biomarker levels
- Inability or unwillingness to provide informed consent
- Severe liver, kidney, or blood disorders
- Current pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Atlas University Faculty of Medicine
Istanbul, Istanbul, Turkey (Türkiye), 34403
Actively Recruiting
Research Team
E
Emine Yildirim, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here